drugs, which Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination.
The U.S. Food and Drug Administration (FDA) approved the first medication (Syfovre) to treat geographic atrophy caused by macular degeneration
drug sold in the U.S. as Syfovre for geographic atrophy. That decision removes the chances of Syfovre reaching the market in Europe, where
There are approx. 23 key companies which are developing the therapies for Geographic Atrophy. The companies which have their Geographic Atrophy drug candidates
The Food and Drug Administration recently approved the first drug to treat geographic atrophy, a form of macular degeneration, which affects a
SYFOVRE is an FDA-approved treatment for Geographic Atrophy (GA)
resources on Syfovre (pegcetacoplan injection), its FDA-approved drug for geographic atrophy secondary to age-related macular degeneration.
The US Food and Drug Administration (FDA) has approved pegcetacoplan injection (Syfovre) as the first treatment for geographic atrophy (GA), a
Symptoms of Geographic Atrophy. Many of the symptoms documented for Geographic Atrophy are the same, or overlap with Dry AMD, so symptoms alone are not the best indicator of Geographic Atrophy, but can include: Difficulty adapting to low light levels; Need for brighter light; Images appear with decreased intensity of brightness; Reduced central
Comments